Premium
Therapeutic potential of RAS prenylation pharmacological inhibitors in the treatment of breast cancer, recent progress, and prospective
Author(s) -
Soleimani Atena,
Amirinejad Mostafa,
Rahsepar Sara,
Vazirian Fatemeh,
Bahrami Afsane,
Ferns Gordon A.,
Khazaei Majid,
Avan Amir,
Hassanian Seyed Mahdi
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27992
Subject(s) - prenylation , breast cancer , medicine , signal transduction , cancer , pharmacology , cancer research , bioinformatics , biology , enzyme , biochemistry
Breast cancer is one of the most prevalent malignancies among women around the world. RAS proteins require posttranslational modifications, including protein prenylation for proper membrane localization and signaling. Regulation of RAS signaling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach in breast cancer therapy. This review summarizes the recent knowledge about the clinical value of RAS prenylation pharmacological inhibitors in breast cancer treatment.